MBT-Candara

 

 

 

Contacts:                                                                                                                                                                                                          Media:
Steve Orndorff                                                                                                                                                                                                 Barbara Lindheim
CEO                                                                                                                                                                                                                  BLL Partners, LLC
MicroBiome Therapeutics                                                                                                                                                                            (212) 584-2276
(303) 544-2104                                                                                                                                                                                              blindheim@bllbiopartners.com

 

MICROBIOME THERAPEUTICS NAMES DISTINGUISHED RESEARCHERS TO ITS CLINICAL ADVISORY BOARD AS IT ADVANCES NM504 FOR DIABETES INDICATIONS

—MBT Is Completing Pilot Studies Testing Microbiome Modulator NM504 for Prediabetes and as Adjunctive Therapy with Metformin—

Broomfield, CO – November 13, 2013 – MicroBiome Therapeutics LLC, (MBT) today reported that a number of distinguished clinical researchers specializing in diabetes and metabolic disorders have joined the Clinical Advisory Board (CAB) that MBT recently established to advance development of lead product NM504. MBT is developing microbiome modulators that alter bacterial populations and their environment in the gastrointestinal (GI) tract to address serious health conditions. Microbiome modulators act on multiple factors in the GI environment, providing specialized ingredients that augment the growth of targeted desirable bacterial strains and discourage the growth of others. These microbiome shifts are designed to positively affect metabolism and weight.

 

“Early data from our pilot studies are encouraging and we are delighted that these leading clinical researchers will be providing guidance to MBT as we prepare for additional clinical trials of NM504 as a potential treatment for diabetes and prediabetes,” noted Steve Orndorff, CEO of Microbiome Therapeutics. “Their expertise in diabetes and metabolic diseases will be invaluable in helping us design the clinical programs for this entirely new therapeutic class.”

 

MBT’s Clinical Advisory Board members include:

 

David D’Alessio, MD, Associate Professor of Medicine, Division of Endocrinology and Albert Vontz Chair in Diabetes Research, University of Cincinnati. Dr. D’Alessio has received national recognition for his work in diabetes and metabolism. His research focuses on gastrointestinal hormones and the regulation of insulin secretion in type 2 diabetes, as well as related aspects of energy metabolism and nutrition.

 

Vivian A. Fonseca, MD, Professor of Medicine, Tullis-Tulane Alumni Chair in Diabetes and Chief of the Endocrinology section at Tulane University Medical Center. Dr. Fonseca is a nationally-recognized researcher and clinician specializing in endocrinology and metabolic disorders. He currently is President for Science and Medicine of the American Diabetes Association and is a former editor-in-chief of Diabetes Care and the Journal of the Metabolic Syndrome and Related Disorders.

 

Frank Greenway, MD, Professor and Director of Outpatient Clinical Research at Pennington Biomedical Research Center, a research campus of Louisiana State University for obesity and metabolic disease. Dr. Greenway is an expert on obesity surgery and nutritional aspects of metabolic disease. He has designed and conducted research studies throughout his career, and has been an investigator for a wide variety of clinical trials assessing therapeutic interventions for diabetes and obesity.

 

David Robbins, MD, Professor of Medicine, University of Kansas Medical School and Director, University of Kansas Diabetes Institute. Dr. Robbins’ research focus is diabetes and metabolism. He is currently principal investigator at the KU Medical Center for an NIH-funded study on prediabetes and vitamin D. Earlier in his career he directed diabetes and obesity clinical research programs at Eli Lilly & Co.

 

NM504 is being studied in two placebo-controlled, double-blinded, proof-of-concept trials. The first is assessing its ability to alter the GI microbiome to enhance insulin sensitivity and fasting blood glucose levels in prediabetic individuals. The second is testing the utility of NM504 as an adjunctive therapy to metformin in diabetes patients with adverse GI effects.

 

MBT’s initial products are combinations of naturally occurring components that are not digested but that act to modulate the GI microbiome in beneficial ways. They are being developed as evidence-based pharmaceutical and medical food products using rigorous scientific methods and clinical studies to assess and validate their beneficial activity.

 

About MicroBiome Therapeutics

MicroBiome Therapeutics LLC (MBT), is a clinical stage biotechnology company developing pharmaceutical and medical food products that aim to improve health status by interacting with and altering the human microbiome. MBT is developing evidence-based microbiome modulators to address serious health conditions. Lead product NM504 is being tested in clinical trials for the management of insulin sensitivity and blood glucose levels and as an adjunct to metformin in patients with prediabetes and type 2 diabetes. For more information, visit www.mbiome.com.